Trinity College is pleased to announce that in partnership with the Department of Business, Innovation and Skills it plans to build the Sir John Bradfield Centre, a new Technology Centre in the heart of the Cambridge Science Park.
Trinity College is pleased to announce that in partnership with the Department of Business, Innovation and Skills it plans to build the Sir John Bradfield Centre, a new Technology Centre in the heart of the Cambridge Science Park. Trinity College, the College of Sir Isaac Newton among many other distinguished scientists, has long been at the centre of scientific innovation in Cambridge University.
The College was an early promoter of technology transfer to industry with the development of the Cambridge Science Park, which is now occupied by more than 90 companies with some 5,000 employees. The College would like to do more to translate Cambridge research into companies and products; particularly in the very early stage companies. It is known that science incubators can help in these early stages, in particular by providing teams and start-up companies with flexible and affordable space, education, mentoring and finance. It is expected that these companies will thrive in the self-sustaining entrepreneurial culture of the new Centre and the Science Park.
Sir Gregory Winter, Master of Trinity College said that ‘Trinity College is pleased to help on all these fronts by providing a highly flexible building at the heart of the Science Park, and working with other partners to help with education, mentoring and seed financing. We hope to promote a culture in which we not only help to develop technologies and companies, but also the entrepreneurs who will build the industries of the future. We are particularly pleased to associate this building with Sir John Bradfield, former Senior Bursar of the College, who was instrumental in the creation of the Cambridge Science Park’.
Notes for Editors:
(a) Sir Gregory Winter – Master of Trinity: is himself a successful scientific entrepreneur. In 1989 he founded Cambridge Antibody Technology, one of the early commercial biotech companies involved in antibody engineering; in 2000, he founded Domantis (now GSK) which pioneered the use of domain antibodies; and in 2009 he founded another company, Bicycle Therapeutics Limited which is trying to develop very small protein mimics.
For press information please contact: Julie Bushell 01223 559331 email